Founded in 1994, Genesis is a biotechnology company based in Auckland, New Zealand, with a history of development of therapeutics for the treatment of cancer and diseases of the immune system.

Genesis has established Solirna Biosciences Ltd to develop a novel single stranded gene silencing technology which acts through the RNAi mechanism.

Our oncology program is employing RNA interference (RNAi), a breakthrough gene silencing technology, to target the growth and drug resistance of cancer cells. The aim of the Zyrogen programme is to use antibody-based therapeutics to target a growth factor we have shown to be implicated in the development of autoimmune and bone disorders.

Genesis' long-term value proposition lies in its commitment to innovation in research and development and commercialising novel sciences. We place high priority on establishing and cultivating productive collaborations with industry partners, thereby fast-tracking the product development process and sharing risks and rewards with partners.